Company Overview of Boehringer Ingelheim Corporation
Boehringer Ingelheim Corporation, through its subsidiaries, discovers, develops, manufactures, and markets human and animal health care products in the United States. It offers cardiovascular, respiratory, HIV, immunology, central nervous system, and urology products; active pharmaceutical ingredients; oral liquids, tablets, and capsules; and products for the treatment of diseases in dogs, cats, horses, cattle, and swine. The company also provides over-the-counter health care products, including Dulcolax, which is used for occasional constipation and irregularity problems; Zantac that is used for the prevention and relief of heartburn; and Mirapex ER, a tablet for the signs and symptoms of i...
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877-0368
Founded in 1984
Key Executives for Boehringer Ingelheim Corporation
Chief Executive Officer, President and Managing Director
Chairman of the Board of Managing Directors
Compensation as of Fiscal Year 2016.
Boehringer Ingelheim Corporation Key Developments
Boehringer Ingelheim Completes Enrollment for Pivotal Phase III Trial
Nov 10 15
Boehringer Ingelheim announced it has completed enrollment for the pivotal Phase III trial of BI695501, a biosimilar candidate to adalimumab. This announcement was made following recent results from a Phase I trial that demonstrated pharmacokinetic bioequivalence with both the U.S.-licensed and EU-approved reference products. These Phase I data for BI695501 were discussed at the American College of Rheumatology /Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in San Francisco. The Phase III clinical trial is a randomized, double-blind, parallel arm, multiple dose, active comparator trial in patients who have been diagnosed with moderate to severe rheumatoid arthritis and are currently being treated with methotrexate. Each participant is randomized to receive either BI695501 or the U.S.-licensed reference product every two weeks for 48 weeks.
Boehringer Ingelheim Announces Results from Phase I Study of its Biosimilar Candidate for Adalimumab
Oct 28 15
Boehringer Ingelheim announced results from a Phase I study (NCT02045979) of its biosimilar candidate (BI695501) for adalimumab (AbbVie's Humira®), that demonstrated pharmacokinetic bioequivalence with both the U.S.-licensed and EU-approved reference products. These data were presented in a poster at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting. The Phase I trial was a randomized, double-blind, single dose, parallel-arm study in healthy individuals: 327 healthy males between the ages of 18 and 55 participated; Each participant was randomized to receive one subcutaneous dose (40mg/0.8mL) of either BI695501, U.S.-licensed or EU-approved adalimumab. The study found that safety, tolerability and immunogenicity were comparable among the treatment groups.
Boehringer Ingelheim Corporation Presents at BioNetwork Partnering Summit, Oct-27-2015 02:00 PM
Aug 14 15
Boehringer Ingelheim Corporation Presents at BioNetwork Partnering Summit, Oct-27-2015 02:00 PM. Venue: The Ritz-Carlton, Laguna Niguel, California, United States. Speakers: John Adamou, Head, BD&L - Strategic Transactions.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|